Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHVNASDAQ:VNDANASDAQ:VSTMNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$2.20-2.7%$3.02$1.84▼$5.31$75.61M1.51260,385 shs817,661 shsVNDAVanda Pharmaceuticals$4.99+2.1%$4.43$3.81▼$6.37$292.90M0.68606,033 shs293,730 shsVSTMVerastem$4.76-1.9%$6.36$2.10▼$9.10$263.76M0.711.26 million shs1.68 million shsXOMAXOMA Royalty$26.43+1.2%$25.28$18.35▼$35.00$322.63M0.9335,079 shs25,289 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%-1.35%-42.56%+0.92%-51.22%VNDAVanda Pharmaceuticals0.00%+4.48%+12.48%+20.63%-6.83%VSTMVerastem0.00%+14.70%-22.85%-7.75%+61.90%XOMAXOMA Royalty0.00%-3.84%+5.74%+35.98%+2.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences1.627 of 5 stars3.80.00.00.02.30.00.6VNDAVanda Pharmaceuticals4.416 of 5 stars3.82.00.04.20.63.31.3VSTMVerastem2.6456 of 5 stars3.53.00.00.01.02.50.6XOMAXOMA Royalty4.4356 of 5 stars3.54.00.03.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.33551.52% UpsideVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50230.40% UpsideVSTMVerastem 3.00Buy$13.38180.99% UpsideXOMAXOMA Royalty 3.00Buy$69.50162.92% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, XOMA, VNDA, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.005/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/17/2025XOMAXOMA RoyaltyBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/AVNDAVanda Pharmaceuticals$198.77M1.48N/AN/A$9.24 per share0.54VSTMVerastem$10K26,156.20N/AN/A($0.65) per share-7.32XOMAXOMA Royalty$28.49M11.11N/AN/A$6.95 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)Latest ACHV, XOMA, VNDA, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34N/AN/AN/A$54.77 millionN/A5/13/2025Q1 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.853.513.51VNDAVanda PharmaceuticalsN/A3.933.91VSTMVerastemN/A3.503.50XOMAXOMA Royalty1.185.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%VNDAVanda Pharmaceuticals88.14%VSTMVerastem88.37%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%VNDAVanda Pharmaceuticals10.00%VSTMVerastem2.10%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2034.69 million33.64 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.04 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableACHV, XOMA, VNDA, and VSTM HeadlinesRecent News About These CompaniesAcuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)July 2 at 9:54 AM | marketbeat.comTop biotech deals in June 2025July 2 at 9:17 AM | labiotech.euLXOMA Royalty (NASDAQ:XOMA) Downgraded to "Hold" Rating by Wall Street ZenJune 29, 2025 | americanbankingnews.comXOMA Royalty (NASDAQ:XOMA) Downgraded by Wall Street Zen to HoldJune 28, 2025 | marketbeat.comXOMA Royalty to Buy Turnstone BiologicsJune 27, 2025 | marketwatch.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comXOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger DealJune 27, 2025 | quiverquant.comQTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightJune 27, 2025 | globenewswire.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?June 24, 2025 | zacks.comXOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | investing.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street ZenJune 14, 2025 | marketbeat.comPositive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy RatingMay 29, 2025 | tipranks.comXOMA boosts stake in anti-CD38 antibody with $30 million dealMay 28, 2025 | thepharmaletter.comTXOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 28, 2025 | benzinga.comXOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy RatingMay 28, 2025 | tipranks.comXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionMay 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, XOMA, VNDA, and VSTM Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$2.20 -0.06 (-2.65%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$2.15 -0.05 (-2.05%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Vanda Pharmaceuticals NASDAQ:VNDA$4.99 +0.10 (+2.13%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Verastem NASDAQ:VSTM$4.76 -0.09 (-1.86%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$4.76 0.00 (0.00%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA Royalty NASDAQ:XOMA$26.43 +0.32 (+1.24%) As of 07/3/2025 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
